Rosacea - A Pipeline Analysis Report

Overview of the drug development pipeline for rosacea

Rosacea is a commonly occurring skin condition that is mistaken for acne, an allergic reaction, or any other skin problems. This skin condition can be aggravated by factors such as alcohol, extreme temperature, sunlight, wind, emotions, hot drinks, spicy food, cosmetics, and drugs prescribed to dilate blood vessels. This disorder is prevalent in numerous symptoms such as facial redness, swollen red bumps, eye problems, and enlarged nose. Technavio’s market research analysts observes that rosacea has higher occurrence in adults aged 30-60 years, women during menopause condition, and people with fair skin.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I/II, phase I, phase II/III, and pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase III stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of rosacea. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• BioPharmX
• Dermata Therapeutics
• Foamix

Therapeutic assessment of the drug development pipeline for rosacea by route of administration

• Oral
• Intravenous

The topical route of administration (ROA) involves the administration of drug substances to body surfaces such as skin or mucous membranes. It has been observed that the majority of total therapeutics for rosacea are being developed for topical administration.

Therapeutic assessment of the drug development pipeline for rosacea by therapeutic modality

• Small molecules
• Biologicals
• peptides

According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for rosacea are being developed as small molecules. These molecules are chemically manufactured active substances that bind with specific biological macromolecules and act as an effector and alter the activity of the target cell.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for rosacea?
• What are the companies that are currently involved in the development of drug development molecules for rosacea?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.